

AIM ImmunoTech Inc.

03:30 02 Apr 2019

Hemispherx Biopharma makes headway in advancing flagship cancer drug Ampligen in 2018

Hemispherx Biopharma Inc (NYSE American:HEB) late on Monday revealed it has made considerable headway in advancing the development of its flagship cancer drug candidate Ampligen as it announced its financial results for 2018.

High on its list of achievements in 2018 was the signing of an agreement with Roswell Park Comprehensive Cancer Center in Buffalo, New York to evaluate Ampligen together with checkpoint inhibitors in the fight against bladder cancer, melanoma and renal cell carcinoma.

READ: Hemispherx rises as five trials for cancer drug Ampligen kick off this year

The Ocala, Florida drug maker also expanded its production to provide a supply of Ampligen for clinical and expanded access programs in the US, Canada, Europe and a commercial program in Argentina.

As of the close of 2018, two trials evaluating Ampligen were underway at a pair of major cancer research centers to test in humans whether Ampligen can be used to change the tumor microenvironment and increase the effectiveness of cancer immunotherapy like checkpoint blockade.

The first is a Phase 2A study treating patients with colorectal cancer that has spread to the liver at Roswell Park Comprehensive Cancer Center. The second is a Phase ½ study to test Ampligen as a combination therapy with chemo-immunotherapy for patients with recurrent ovarian cancer at the University of Pittsburgh Medical Center.

READ: Hemispherx Biopharma started with a Buy rating at Ascendant Capital Markets

Looking ahead to other clinical trials in the US, Hemispherx is also working with the University of Pittsburgh Medical Center, Roswell Park's Comprehensive Cancer Center and the University of Nebraska Medical Center— to study Ampligen in pre-clinical and clinical studies for the treatment of nine cancer types: renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian, breast, colorectal, urothelial, prostate and pancreatic cancer.

On top of this, the Florida company is also supplying Ampligen to an Expanded Access program in Europe at the Erasmus Medical Center in the Netherlands, which is treating pancreatic cancer patients with Ampligen.

Financial results in focus


The company's research and development expenses in 2018 came to \$4.78 million compared with \$4.098 million in 2017.

In other news, its net loss from continuing operations amounted to \$9.81 million, or \$0.22 per share, against \$8.259 million, or \$0.29 per share, in 2017. The increase in the loss stemmed partly from manufacturing expenses for the 16,000 vials of Ampligen filled and finished in 2018.

Price: 0.6

Market Cap: \$2.9 m

1 Year Share Price Graph



October 2018 April 2019 October 2019

Share Information

Code: AIM

Listing: NYSE

52 week **High** **Low**
 14.8104 **0.5522**

Sector: Pharma & Biotech

Website: aimimmuno.com

Company Synopsis:

AIM ImmunoTech Inc. is an immunopharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.

action@proactiveinvestors.com

As of December, Hemispherx had cash and cash equivalents of \$1.825 million.

Hemispherx's two key drugs are Ampligen, which fights both cancer and chronic fatigue syndrome, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx shares closed up 1.88% to finish at \$0.16 on Monday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).